Assessment of the High Risk and Unmet Need in Patients With Coronary Artery Disease and Type 2 Diabetes: A Descriptive Retrospective Cohort Study (ATHENA)

Abstract. Objective:. Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) filled an important data gap by showing a significant reduction of ischemic cardiovascular events in a ticagrelor plus aspirin cohort compared with placebo plus aspirin cohort among patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Liya Bian, Miaohan Qiu, Jing Li, Lijiao Zhang, Phillip R Hunt, Marco Kuster, Yaling Han, Hanjia Gao, Xiaoxia Fu
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2024-12-01
Series:Cardiology Discovery
Online Access:http://journals.lww.com/10.1097/CD9.0000000000000133
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850213890266234880
author Liya Bian
Miaohan Qiu
Jing Li
Lijiao Zhang
Phillip R Hunt
Marco Kuster
Yaling Han
Hanjia Gao
Xiaoxia Fu
author_facet Liya Bian
Miaohan Qiu
Jing Li
Lijiao Zhang
Phillip R Hunt
Marco Kuster
Yaling Han
Hanjia Gao
Xiaoxia Fu
author_sort Liya Bian
collection DOAJ
description Abstract. Objective:. Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) filled an important data gap by showing a significant reduction of ischemic cardiovascular events in a ticagrelor plus aspirin cohort compared with placebo plus aspirin cohort among patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) but without a history of myocardial infarction. This study aims to evaluate the applicability of the THEMIS results in a real-world clinical setting in China. Methods:. This retrospective, observational cohort study used data from the Optimal antiPlatelet Therapy for Chinese patients with Coronary Artery Disease (OPT-CAD) study which enrolled participants who were hospitalized between November 2012 and December 2013. The 24-month cumulative incidence of major adverse cardiovascular event (MACE), major bleeding, and all-cause death in patients with T2DM and CAD (T2DM-CAD), T2DM and stable CAD (SCAD)(T2DM-SCAD), and T2DM and SCAD without prior myocardial infarction or stroke (THEMIS-like) were analyzed. Results:. Data from 13,296 patients with CAD were included; the T2DM-CAD, T2DM-SCAD, and THEMIS-like cohorts comprised 3,344 (25.2%), 949 (7.1%), and 509 (3.8%) patients, respectively. The corresponding 24-month cumulative incidence of major bleeding was 38 (1.1%), 16 (1.7%), and 8 (1.6%), and that of MACEs was 250 (7.5%), 87 (9.2%), and 29 (5.7%), and all-cause death was 181 (5.4%), 84 (8.9%), 29 (5.7%), respectively. The risk of MACE in the THEMIS-like cohort was approximate to that in the THEMIS trial (7.7% vs. 8.5% in ticagrelor and placebo group, respectively). Conclusion:. The incidence of MACE was substantial in the THEMIS-like cohort, suggesting that cardiovascular risk for future events correlates with the presence of cardiovascular disease across the CAD risk continuum.
format Article
id doaj-art-9ae415fccffd42e995469fb892360a6f
institution OA Journals
issn 2096-952X
2693-8499
language English
publishDate 2024-12-01
publisher Wolters Kluwer Health/LWW
record_format Article
series Cardiology Discovery
spelling doaj-art-9ae415fccffd42e995469fb892360a6f2025-08-20T02:09:02ZengWolters Kluwer Health/LWWCardiology Discovery2096-952X2693-84992024-12-014425325910.1097/CD9.0000000000000133202412000-00001Assessment of the High Risk and Unmet Need in Patients With Coronary Artery Disease and Type 2 Diabetes: A Descriptive Retrospective Cohort Study (ATHENA)Liya Bian0Miaohan Qiu1Jing Li2Lijiao Zhang3Phillip R Hunt4Marco Kuster5Yaling Han6Hanjia GaoXiaoxia Fu1 State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, China1 State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, China1 State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, China2 Medical Affairs, AstraZeneca, Shanghai 200041, China3 Cardiovascular, Renal and Metabolism, Global Medical Affairs, AstraZeneca, Gaithersburg, Maryland 20878, USA4 Medical Affairs, Lead Vaccines & Infectious Disease, AstraZeneca, Baar, Zug 6340, Switzerland1 State Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, ChinaAbstract. Objective:. Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) filled an important data gap by showing a significant reduction of ischemic cardiovascular events in a ticagrelor plus aspirin cohort compared with placebo plus aspirin cohort among patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) but without a history of myocardial infarction. This study aims to evaluate the applicability of the THEMIS results in a real-world clinical setting in China. Methods:. This retrospective, observational cohort study used data from the Optimal antiPlatelet Therapy for Chinese patients with Coronary Artery Disease (OPT-CAD) study which enrolled participants who were hospitalized between November 2012 and December 2013. The 24-month cumulative incidence of major adverse cardiovascular event (MACE), major bleeding, and all-cause death in patients with T2DM and CAD (T2DM-CAD), T2DM and stable CAD (SCAD)(T2DM-SCAD), and T2DM and SCAD without prior myocardial infarction or stroke (THEMIS-like) were analyzed. Results:. Data from 13,296 patients with CAD were included; the T2DM-CAD, T2DM-SCAD, and THEMIS-like cohorts comprised 3,344 (25.2%), 949 (7.1%), and 509 (3.8%) patients, respectively. The corresponding 24-month cumulative incidence of major bleeding was 38 (1.1%), 16 (1.7%), and 8 (1.6%), and that of MACEs was 250 (7.5%), 87 (9.2%), and 29 (5.7%), and all-cause death was 181 (5.4%), 84 (8.9%), 29 (5.7%), respectively. The risk of MACE in the THEMIS-like cohort was approximate to that in the THEMIS trial (7.7% vs. 8.5% in ticagrelor and placebo group, respectively). Conclusion:. The incidence of MACE was substantial in the THEMIS-like cohort, suggesting that cardiovascular risk for future events correlates with the presence of cardiovascular disease across the CAD risk continuum.http://journals.lww.com/10.1097/CD9.0000000000000133
spellingShingle Liya Bian
Miaohan Qiu
Jing Li
Lijiao Zhang
Phillip R Hunt
Marco Kuster
Yaling Han
Hanjia Gao
Xiaoxia Fu
Assessment of the High Risk and Unmet Need in Patients With Coronary Artery Disease and Type 2 Diabetes: A Descriptive Retrospective Cohort Study (ATHENA)
Cardiology Discovery
title Assessment of the High Risk and Unmet Need in Patients With Coronary Artery Disease and Type 2 Diabetes: A Descriptive Retrospective Cohort Study (ATHENA)
title_full Assessment of the High Risk and Unmet Need in Patients With Coronary Artery Disease and Type 2 Diabetes: A Descriptive Retrospective Cohort Study (ATHENA)
title_fullStr Assessment of the High Risk and Unmet Need in Patients With Coronary Artery Disease and Type 2 Diabetes: A Descriptive Retrospective Cohort Study (ATHENA)
title_full_unstemmed Assessment of the High Risk and Unmet Need in Patients With Coronary Artery Disease and Type 2 Diabetes: A Descriptive Retrospective Cohort Study (ATHENA)
title_short Assessment of the High Risk and Unmet Need in Patients With Coronary Artery Disease and Type 2 Diabetes: A Descriptive Retrospective Cohort Study (ATHENA)
title_sort assessment of the high risk and unmet need in patients with coronary artery disease and type 2 diabetes a descriptive retrospective cohort study athena
url http://journals.lww.com/10.1097/CD9.0000000000000133
work_keys_str_mv AT liyabian assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena
AT miaohanqiu assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena
AT jingli assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena
AT lijiaozhang assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena
AT philliprhunt assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena
AT marcokuster assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena
AT yalinghan assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena
AT hanjiagao assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena
AT xiaoxiafu assessmentofthehighriskandunmetneedinpatientswithcoronaryarterydiseaseandtype2diabetesadescriptiveretrospectivecohortstudyathena